BIOMAT Database Logo BIOMAT Database Logo

Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. 2007

Narikazu Boku, and Atsushi Ohtsu, and Shigeaki Yoshida, and Kuniaki Shirao, and Yasuhiro Shimada, and Ichinosuke Hyodo, and Hiroshi Saito, and Yoshinori Miyata, and
Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan. n.boku@scchr.jp

BACKGROUND Our previous phase II study of 5-fluorouracil (5-FU) and cisplatin (FP) for treatment of advanced gastric cancer showed that strong immunoreactivity for vascular endothelial growth factor (VEGF) is associated with chemoresponse. Patients with four or five of the favorable phenotypes, p53 (-), bcl-2 (-), gluthathione S-transferase pi (-), thymidylate synthase (-), and VEGF (+), survived longer than those with three or less of these phenotypes. The purpose of this study is to confirm our previous results and to compare the significance of those markers between continuous infusion of 5-FU (5-FUci) and FP. METHODS Pretreatment biopsies from 131 of 210 advanced gastric cancer patients enrolled to JCOG9205 were analyzed immunohistochemically for the presence of the five markers. RESULTS Median survival times of patients treated with 5-FUci (n = 65) or FP (n = 66) were 216 and 253 days, respectively (P = 0.6953). After FP treatment, patients with four or five favorable phenotypes (n = 20) survived longer than those with three or less favorable phenotypes (n = 46) (334 days and 243 days, respectively; P = 0.0463), and the survival times of 34 and 32 patients with VEGF (-) and (+) were similar (269 days and 253 days, respectively; P = 0.6317). After 5-FUci, 30 patients with VEGF (+) survived for a shorter time than 35 patients with VEGF (-) (142 days and 302 days, respectively; P = 0.0043). CONCLUSIONS The number of favorable phenotypes is prognostic for gastric cancer patients treated with FP, and VEGF has a different impact on survival between treatment with 5-FUci and FP.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005982 Glutathione Transferase A transferase that catalyzes the addition of aliphatic, aromatic, or heterocyclic FREE RADICALS as well as EPOXIDES and arene oxides to GLUTATHIONE. Addition takes place at the SULFUR. It also catalyzes the reduction of polyol nitrate by glutathione to polyol and nitrite. Glutathione S-Alkyltransferase,Glutathione S-Aryltransferase,Glutathione S-Epoxidetransferase,Ligandins,S-Hydroxyalkyl Glutathione Lyase,Glutathione Organic Nitrate Ester Reductase,Glutathione S-Transferase,Glutathione S-Transferase 3,Glutathione S-Transferase A,Glutathione S-Transferase B,Glutathione S-Transferase C,Glutathione S-Transferase III,Glutathione S-Transferase P,Glutathione Transferase E,Glutathione Transferase mu,Glutathione Transferases,Heme Transfer Protein,Ligandin,Yb-Glutathione-S-Transferase,Glutathione Lyase, S-Hydroxyalkyl,Glutathione S Alkyltransferase,Glutathione S Aryltransferase,Glutathione S Epoxidetransferase,Glutathione S Transferase,Glutathione S Transferase 3,Glutathione S Transferase A,Glutathione S Transferase B,Glutathione S Transferase C,Glutathione S Transferase III,Glutathione S Transferase P,Lyase, S-Hydroxyalkyl Glutathione,P, Glutathione S-Transferase,Protein, Heme Transfer,S Hydroxyalkyl Glutathione Lyase,S-Alkyltransferase, Glutathione,S-Aryltransferase, Glutathione,S-Epoxidetransferase, Glutathione,S-Transferase 3, Glutathione,S-Transferase A, Glutathione,S-Transferase B, Glutathione,S-Transferase C, Glutathione,S-Transferase III, Glutathione,S-Transferase P, Glutathione,S-Transferase, Glutathione,Transfer Protein, Heme,Transferase E, Glutathione,Transferase mu, Glutathione,Transferase, Glutathione,Transferases, Glutathione
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000964 Antimetabolites, Antineoplastic Antimetabolites that are useful in cancer chemotherapy. Antineoplastic Antimetabolites

Related Publications

Narikazu Boku, and Atsushi Ohtsu, and Shigeaki Yoshida, and Kuniaki Shirao, and Yasuhiro Shimada, and Ichinosuke Hyodo, and Hiroshi Saito, and Yoshinori Miyata, and
Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.
May 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
Narikazu Boku, and Atsushi Ohtsu, and Shigeaki Yoshida, and Kuniaki Shirao, and Yasuhiro Shimada, and Ichinosuke Hyodo, and Hiroshi Saito, and Yoshinori Miyata, and
Salvage Treatment for Advanced Gastric Cancer Using FEP (5-FU, Etoposide, Cisplatin) Combination Chemotherapy.
October 2002, Cancer research and treatment,
Narikazu Boku, and Atsushi Ohtsu, and Shigeaki Yoshida, and Kuniaki Shirao, and Yasuhiro Shimada, and Ichinosuke Hyodo, and Hiroshi Saito, and Yoshinori Miyata, and
Cisplatin, doxorubicin, and 5-FU in combination for advanced gastric cancer.
October 1984, Cancer treatment reports,
Narikazu Boku, and Atsushi Ohtsu, and Shigeaki Yoshida, and Kuniaki Shirao, and Yasuhiro Shimada, and Ichinosuke Hyodo, and Hiroshi Saito, and Yoshinori Miyata, and
[Arterial infusion chemotherapy for advanced gastric cancer by sequential MTX/5-FU].
September 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
Narikazu Boku, and Atsushi Ohtsu, and Shigeaki Yoshida, and Kuniaki Shirao, and Yasuhiro Shimada, and Ichinosuke Hyodo, and Hiroshi Saito, and Yoshinori Miyata, and
[Trial of outpatient anti-cancer chemotherapy with infusion of 5-FU and cisplatin for advanced gastric and colorectal cancers].
February 2005, Gan to kagaku ryoho. Cancer & chemotherapy,
Narikazu Boku, and Atsushi Ohtsu, and Shigeaki Yoshida, and Kuniaki Shirao, and Yasuhiro Shimada, and Ichinosuke Hyodo, and Hiroshi Saito, and Yoshinori Miyata, and
Combination chemotherapy of cisplatin and 5-FU in advanced colorectal carcinoma.
April 1986, Cancer treatment reports,
Narikazu Boku, and Atsushi Ohtsu, and Shigeaki Yoshida, and Kuniaki Shirao, and Yasuhiro Shimada, and Ichinosuke Hyodo, and Hiroshi Saito, and Yoshinori Miyata, and
Cisplatin plus continuous infusion of 5-fluorouracil for 5 days effective for patients with advanced gastric cancer.
October 1991, Anti-cancer drugs,
Narikazu Boku, and Atsushi Ohtsu, and Shigeaki Yoshida, and Kuniaki Shirao, and Yasuhiro Shimada, and Ichinosuke Hyodo, and Hiroshi Saito, and Yoshinori Miyata, and
Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma.
January 2003, Anticancer research,
Narikazu Boku, and Atsushi Ohtsu, and Shigeaki Yoshida, and Kuniaki Shirao, and Yasuhiro Shimada, and Ichinosuke Hyodo, and Hiroshi Saito, and Yoshinori Miyata, and
A combination chemotherapy of 5-fluorouracil and cisplatin against advanced gastric cancer.
January 1999, Hepato-gastroenterology,
Narikazu Boku, and Atsushi Ohtsu, and Shigeaki Yoshida, and Kuniaki Shirao, and Yasuhiro Shimada, and Ichinosuke Hyodo, and Hiroshi Saito, and Yoshinori Miyata, and
[Combination chemotherapy for gastric cancer including LV/5-FU].
November 2004, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!